Macro­Gen­ics scores first FDA ap­proval with breast can­cer med Mar­gen­za in third-line pa­tients

In the sus­tain­ably hot on­col­o­gy field, breast can­cer has at­tract­ed some of the biggest play­ers on the mar­ket, in­clud­ing block­buster meds from Roche and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.